KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Interest & Investment Income (2016 - 2020)

Historic Interest & Investment Income for Supernus Pharmaceuticals (SUPN) over the last 10 years, with Q3 2020 value amounting to $3.3 million.

  • Supernus Pharmaceuticals' Interest & Investment Income fell 4132.04% to $3.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was $18.4 million, marking a year-over-year decrease of 881.19%. This contributed to the annual value of $13.8 million for FY2018, which is 38334.5% up from last year.
  • As of Q3 2020, Supernus Pharmaceuticals' Interest & Investment Income stood at $3.3 million, which was down 4132.04% from $4.2 million recorded in Q2 2020.
  • Supernus Pharmaceuticals' 5-year Interest & Investment Income high stood at $5.6 million for Q3 2019, and its period low was $327000.0 during Q1 2016.
  • For the 5-year period, Supernus Pharmaceuticals' Interest & Investment Income averaged around $2.4 million, with its median value being $1.2 million (2018).
  • In the last 5 years, Supernus Pharmaceuticals' Interest & Investment Income skyrocketed by 45853.66% in 2018 and then plummeted by 4132.04% in 2020.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Interest & Investment Income stood at $396000.0 in 2016, then surged by 117.68% to $862000.0 in 2017, then surged by 423.43% to $4.5 million in 2018, then increased by 23.2% to $5.6 million in 2019, then plummeted by 41.32% to $3.3 million in 2020.
  • Its last three reported values are $3.3 million in Q3 2020, $4.2 million for Q2 2020, and $5.6 million during Q3 2019.